Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Biotechnology
Japan’s Takeda Pharmaceutical and TiGenix have announced that at the end of the second acceptance period, Takeda will hold over 96% of all ordinary shares of the Belgian biotech. 6 July 2018
Pharmaceutical
Sinclair Pharma stock was up nearly 35% at 24.7p in early afternoon trading on Thursday following the announcement of better-than-expected financial as well as a takeover approach. 6 July 2018
Pharmaceutical
Juniper Pharmaceuticals has entered into a definitive agreement for Catalent to acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash. 5 July 2018
Biotechnology
East Coast, USA-based firm Athenexhas announced several key strategic deals focused on China, aimed at furthering its oncology developments. 3 July 2018
Pharmaceutical
Vicore Pharma saw its shares rocket 29.57% to 14.90 Swedish kronor, after it announced an agreement to acquire INIM Pharma, a fellow Sweden-based biopharmaceutical company. 3 July 2018
Pharmaceutical
France’s largest drugmaker Sanofi pleased investors this morning with plans to expand its scientific presence in China, which pushed the firm’s share 1.9% higher to 70.10 euros by late morning trading. 3 July 2018
Pharmaceutical
Last week’s clinical trial news included good and bad results. Roche’s latest data on Tecentriq was impressive in lung cancer, but Summit Therapeutics had a huge disappointment with its ezutromid in Duchenne muscular dystrophy (DMD). The US Food and Drug Administration’s approval of the first cannabinoid drug, GW Pharmaceuticals’ Epidiolex for rare forms of epilepsy caused a bit of s stir, while on the negative side, Pain Therapeutics looks set for another FDA rejection for pain drug Remoxy ER. On the M&A front, Novartis has at long last made a decision on the future of its eye care division Alcon. 1 July 2018
Pharmaceutical
US firms Akebia Therapeutics and Keryx Biopharmaceuticals have announced a definitive merger agreement under which the companies will combine in an all-stock merger. 29 June 2018
Pharmaceutical
Stock market reaction provided further evidence of the tech giant Amazon’s potential to disrupt US healthcare on Thursday, after its acquisition of the online pharmacy group PillPack. 29 June 2018
Biosimilars
As Samsung Bioepis continues to advance its pipeline of biosimilar drugs, its US minority partner Biogen has announced its intention to increase its equity stake in the joint venture company. 29 June 2018
Pharmaceutical
Continuing his firm’s strategic concentration on prescription medicines, new Novartis chief executive Vas Narasimhan has announced plans to spin out eyecare division Alcon into a separately-traded company. 29 June 2018
Pharmaceutical
Just 10% of shareholders in Japanese drugmaker Takeda supported a bid to derail the proposed $62 billion takeover of rare disease specialist Shire. 28 June 2018
Pharmaceutical
In a major restructuring, privately-held Switzerland-based healthcare company Roivant Sciences has created two new business units, Roivant Pharma and Roivant Health, to focus its efforts on accelerating the launch of new innovative healthcare companies, including ‘Vants’ oriented around earlier-stage scientific platforms. 28 June 2018
Generics
Having announced in April that it is discussing the sale of Zentiva, French pharma major Sanofi says it has now concluded negotiations for the acquisition of its European generics business, by Advent International. 28 June 2018
Pharmaceutical
Bio-Techne has reached agreement to acquire Waltham, MA-based Exosome Diagnostics. 26 June 2018
Biosimilars
Roche’s proposed acquisition of the already partially-owned Foundations Medicine was seen as another targeted cancer drug deal for the Swiss pharma giant. On the regulatory front, there was the clinical hold from the US Food and Drug Administration of Ziopharm Oncology’s CAR-T therapy. Also FDA Commissioner Scott Gottlieb said he was withdrawing the draft guidance in biosimilar, which has raised concerns from industry. Clinical trial results news included one positive story with positive news on Sarepta Therapeutics’ Duchenne muscular dystrophy drug, named rAAVrh.74.MHCK7, sending the firm’s shares rocketing, and negative outcomes for Anika Therapeutics’ osteoporosis candidate Cingal failing in Phase III. 24 June 2018
Pharmaceutical
London-based buyout fund CVC Capital Partners is in advanced discussions to acquire a controlling stake worth more than 3 billion euros ($3.5 billion) in Italian drugmaker Recordati, the Financial Times reported this morning, citing three people familiar with the transaction. 20 June 2018
Pharmaceutical
French pharma major Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as executive vice president, chief financial officer (CFO) and member of the executive committee, effective October 1, 2018. 19 June 2018
Pharmaceutical
Swiss pharma giant Roche has entered into a definitive merger agreement for Roche to acquire the outstanding shares of Foundation Medicines common stock not already owned by Roche and its affiliates at a price of $137.00 per share in cash. 19 June 2018
Pharmaceutical
Florida, USA-based Nutriband (OTCQB: NTRB), has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies. 14 June 2018
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze